This invention relates to a proprietary recombinant metapneumovirus strain we engineered as a versatile Live-Attenuated Viral vaccine platform that can express several antigens of interest. METAVAC® patent was exclusively licensed worldwide to Vaxxel, a spin-off from the International Research Laboratory #RESPIVIR France – Canada.
Based on the METAVAC® technology, Vaxxel is developing the first intranasal bivalent vaccine candidate against human Respiratory Syncytial Virus (RSV) and human Metapneumovirus (HMPV). Validated at preclinical in vivo stage and associated with a scalable production process for manufacturing, the bivalent Metavac®-RSV candidate could be a promising new option to protect children, at-risk young adults, and the elderly populations who need appropriate specific prophylactic strategies.
This work was supported by Virnext, Vaxxel, Université Laval, Centre de recherche CHU Québec, Université Claude Bernard, Ezus Lyon, Lyon Ingenierie Projet, Pulsalys, Agence Nationale de la Recherche, Association Nationale de la Recherche Scientifique, Region Auvergne Rhône-Alpes, Innobiovir, Ministère de l’Enseignement Supérieur et de la Recherche, Bpi France, INSERM, and CNRS.
Virnext is very proud to have contributed to this granted innovation for fighting seasonal epidemic pneumovirus infections, which pose major public health challenges. Virnext’s commitment is part of the national and European sovereignty approach to the means of protection against emerging and re-emerging infectious diseases. It also aims to contribute to the development of French industries and start-ups like Vaxxel in the Auvergne-Rhône-Alpes region and their international competitiveness.
See on espacenet website:
Read the full articles :
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963613/pdf/vaccines-07-00164.pdf
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11187144/pdf/41541_2024_Article_899.pdf